Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, Phase I dose escalation study of theliatinib monotherapy in wild-type EGFR NSCLC

Next Previous
X
Search
Trial Profile

An open-label, Phase I dose escalation study of theliatinib monotherapy in wild-type EGFR NSCLC

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Xiliertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 27 Sep 2016 New trial record
    • 02 Aug 2016 According to a Chi-Med media release, this study has completed eight once-daily dose cohorts. The maximum tolerated dose has not yet been reached and dose escalation is continuing. company expects to conclude Phase II dose from this trial by the end of 2016.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top